Head to Head Comparison: Johnson & Johnson (NYSE:JNJ) & Virbac (OTC:VRBCF)

Virbac (OTC:VRBCFGet Free Report) and Johnson & Johnson (NYSE:JNJGet Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.


This table compares Virbac and Johnson & Johnson’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Virbac N/A N/A N/A
Johnson & Johnson 13.35% 36.72% 14.62%

Valuation and Earnings

This table compares Virbac and Johnson & Johnson’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virbac N/A N/A N/A $6.61 43.70
Johnson & Johnson $94.94 billion 4.45 $17.94 billion $4.94 32.88

Johnson & Johnson has higher revenue and earnings than Virbac. Johnson & Johnson is trading at a lower price-to-earnings ratio than Virbac, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

24.3% of Virbac shares are owned by institutional investors. Comparatively, 68.4% of Johnson & Johnson shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


Virbac pays an annual dividend of $1.90 per share and has a dividend yield of 0.7%. Johnson & Johnson pays an annual dividend of $4.76 per share and has a dividend yield of 2.9%. Virbac pays out 28.7% of its earnings in the form of a dividend. Johnson & Johnson pays out 96.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has raised its dividend for 62 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of current recommendations for Virbac and Johnson & Johnson, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virbac 0 1 0 0 2.00
Johnson & Johnson 0 9 5 0 2.36

Johnson & Johnson has a consensus target price of $170.65, indicating a potential upside of 5.07%. Given Johnson & Johnson’s stronger consensus rating and higher probable upside, analysts plainly believe Johnson & Johnson is more favorable than Virbac.


Johnson & Johnson beats Virbac on 11 of the 14 factors compared between the two stocks.

About Virbac

(Get Free Report)

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Receive News & Ratings for Virbac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virbac and related companies with MarketBeat.com's FREE daily email newsletter.